Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.

Application

Fulvestrant is used for the treatment of hormone receptor positive metastatic breast cancer or locally advanced unresectable disease in postmenopausal women; it is given by injection.A 2017 Cochrane review found it is as safe and effective as first line or second line endocrine therapy.

It is also used to treat HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after first-line endocrine therapy.Due to the medication's having a chemical structure similar to that of estrogen, it can interact with immunoassays for blood estradiol concentrations and show falsely elevated results.This can improperly lead to discontinuing the treatment.

Pharmacology

Mechanism of Action

Breast cancer: Competitively binds to estrogen receptors on tumors and other tissue targets, producing nuclear complex that decreases DNA synthesis and inhibits estrogen effects; no estrogen-receptor agonist activity; downregulates estrogen receptors and inhibits breast tumor growth

Precocious puberty (off-label): Estrogen receptor antagonist

Absorption

Peak Plasma Time: 7 days

Duration: Plasma levels detected for 1 month

Distribution

Protein Bound: 99%

Vd: 3-5 L/kg

Metabolism

Via multiple hepatic pathways

Excretion

Half-Life: 40 days
Excretion: Feces >90%; urine <1%

Cautions

Caution in bleeding diathesis, thrombocytopenia, therapeutic anticoagulation

Systemic exposure was increased in patients with moderate hepatic impairment (see Dosage Modifications)

Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception;

Therapy can interfere with estradiol measurement by immunoassay, resulting in falsely elevated estradiol levels;

Injection site related events including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy reported; caution should be taken while administering therapy at dorsogluteal injection site due to proximity of underlying sciatic nerve.